Suppr超能文献

是否应推荐使用润肤剂预防特应性皮炎?——新证据与当前知识状况

Should Emollients Be Recommended for the Prevention of Atopic Dermatitis?-New Evidence and Current State of Knowledge.

作者信息

Grześk-Kaczyńska Magdalena, Petrus-Halicka Justyna, Kaczyński Szymon, Bartuzi Zbigniew, Ukleja-Sokołowska Natalia

机构信息

Department and Clinic of Allergy, Clinical Immunology and Internal Diseases, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland.

Department of Obstetrics, Gynecology and Gynecological Oncology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 87-100 Torun, Poland.

出版信息

J Clin Med. 2024 Feb 1;13(3):863. doi: 10.3390/jcm13030863.

Abstract

INTRODUCTION

Atopic dermatitis (AD) is a chronic, pruritic skin disease with complex pathogenesis, which affects about 43 million children aged 1-4 years. One of the most known methods of alleviating symptoms of AD is emollient treatment, which varies depending on formulation and additional active ingredients. There is some evidence that emollients could be used in AD prevention in high-risk children.

MATERIALS AND METHODS

A search of the literature from Cochrane Library, PubMed and Medline was conducted between August and September 2023 with the following keywords: "atopic dermatitis", "emollients", and "prevention". Only randomised clinical trials published in the last 5 years were included into the meta-analysis.

RESULTS

Considering the inclusion criteria only 11 randomized clinical trials were taken into account, and six of them proved lack of effect of emollients in the prevention of atopic dermatitis among neonates from AD risk groups.

CONCLUSIONS

Emollient treatment has a good safety profile and most of the ingredients used in formulations are nonirritant for sensitive newborn and infant skin. There is some evidence of the positive effects of emollient treatment in prevention of AD in predisposed populations. The relatively high cost of emollient treatment (vs regular infant skin-care routine) would support the necessity for further evaluation of their effectiveness in nonpredisposed populations.

摘要

引言

特应性皮炎(AD)是一种发病机制复杂的慢性瘙痒性皮肤病,影响约4300万1至4岁的儿童。缓解AD症状最常用的方法之一是润肤治疗,其因配方和其他活性成分而异。有证据表明,润肤剂可用于高危儿童的AD预防。

材料与方法

于2023年8月至9月期间在Cochrane图书馆、PubMed和Medline数据库中检索文献,关键词如下:“特应性皮炎”、“润肤剂”和“预防”。纳入荟萃分析的仅为过去5年发表的随机临床试验。

结果

根据纳入标准,仅考虑了11项随机临床试验,其中6项证明润肤剂对AD风险组新生儿预防特应性皮炎无效。

结论

润肤治疗具有良好的安全性,配方中使用的大多数成分对敏感的新生儿和婴儿皮肤无刺激性。有证据表明润肤治疗对易感人群预防AD有积极作用。润肤治疗(与常规婴儿皮肤护理相比)成本相对较高,这支持了有必要进一步评估其在非易感人群中的有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验